SCHEMBL7112609

SCHEMBL7112609

Cc1cc([N+](=O)[O-])ccc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.59
ALDH1A1 P00352 4/20 0.58
TDP1 Q9NUW8 3/20 0.58
TSHR P16473 2/20 0.58
POLB P06746 1/20 0.58
RAB9A P51151 1/20 0.58
CYP3A4 P08684 3/20 0.55
AKR1C3 P42330 1/20 0.55
AKR1C2 P52895 1/20 0.55
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CRHBP P24387 1/20 0.51
CYP2C19 P33261 1/20 0.51
CRHR2 Q13324 1/20 0.51
PTPRC P08575 2/20 0.50
ESR2 Q92731 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14154089 0.89 ALDH1A1 (0.62) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL629839 0.86 PTGS2 (0.59) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL30683694 0.85 ALDH1A1 (0.72) ALDH1A1TDP1TSHRCYP3A4KMT2A
SCHEMBL14565383 0.84 TSHR (0.60) ALDH1A1TDP1TSHRCYP3A4KMT2A
SCHEMBL6391559 0.83 PTGS2 (0.69) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL28207049 0.83 PTGS2 (0.73) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL9807396 0.83 ALDH1A1 (0.55) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL3828843 0.83 ALDH1A1 (0.55) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL22130321 0.83 ALDH1A1 (0.61) PTGS2ALDH1A1TDP1TSHRPOLB
SCHEMBL3540919 0.83 ALDH1A1 (0.55) PTGS2ALDH1A1TDP1TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101245018-B Process for producing 2-nitryl fluorenone UNIV SHANXI 2011-05-18 CN disclosed
US-7943645-B2 Piperidine compounds for use as orexin receptor antagonist SMITHKLINE BEECHAM LIMITED (GB) 2011-05-17 US disclosed
US-20090082390-A1 PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST SMITHKLINE BEECHAM P.L.C. 2009-03-26 US disclosed
US-7423052-B2 Piperidine compounds for use as orexin receptor antagoinst SMITHKLINE BEECHAM P.L.C. (GB) 2008-09-09 US disclosed
CN-101245018-A Process for producing 2-nitryl fluorenone UNIV SHANXI (CN) 2008-08-20 CN disclosed
CN-1152006-C Biphenyl derivatives - 2004-06-02 CN disclosed
EP-1047665-B1 MATRIX METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-10-22 EP disclosed
US-6423519-B1 CONTACTING FUNGAL CELL WITH COMPOUND WHICH INHIBITS PRENYLTRANSFERASE ACTIVITY OF CELL, INCLUDING PERMEASE TAG WHICH FACILITATES PERMEASE-MEDIATED TRANSPORT OF COMPOUND INTO CELL, INHIBITING GROWTH THEREOF GPC BIOTECH INC. 2002-07-23 US disclosed
CN-1343197-A Biphenyl derivatives as neurokinin-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2002-04-03 CN disclosed
US-6350907-B1 PEPTIDE ENZYME INHIBITORS PFIZER INC 2002-02-26 US disclosed
EP-1144381-A2 SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GmbH (DE) 2001-10-17 EP disclosed
EP-1133475-A1 SUBSTITUTED BENZO DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GmbH (DE) 2001-09-19 EP disclosed
EP-1096925-A2 USE OF INHIBITORS OF PRENYLTRANSFERASES FOR FOR INHIBITING FUNGAL GROWTH MITOTIX, INC. (US) 2001-05-09 EP disclosed
CN-1284942-A matrix metalloproteinase inhibitors PFIZER LTD (US) 2001-02-21 CN disclosed
EP-1047665-A1 MATRIX METALLOPROTEASE INHIBITORS Pfizer Limited (GB) 2000-11-02 EP disclosed
WO-2000003743-A9 USE OF INHIBITORS OF PRENYLTRANSFERASES FOR INHIBITING FUNGAL GROWTH MITOTIX INC (US) 2000-07-27 WO disclosed
WO-2000032577-A2 SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GMBH (DE) 2000-06-08 WO disclosed
WO-2000031039-A1 SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GMBH (DE) 2000-06-02 WO disclosed
WO-2000003743-A2 USE OF INHIBITORS OF PRENYLTRANSFERASES FOR INHIBITING FUNGAL GROWTH MITOTIX, INC. (US) 2000-01-27 WO disclosed
WO-1999035124-A1 MATRIX METALLOPROTEASE INHIBITORS PFIZER LIMITED (GB) 1999-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082390-A1 PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST HCRTR2, HCRTR1, OXTR PTGS2 1831/4885ALDH1A1 1534/4885TDP1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.